WithdrawnPhase 3NCT04065165
Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome
Studying Neuroendocrine tumor of the small intestine
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Principal Investigator
- Juan ValleThe Christie NHS Foundation Trust, Manchester, UK
- Intervention
- Telotristat Ethyl(drug)
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2027
Collaborators
Ipsen
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04065165 on ClinicalTrials.govOther trials for Neuroendocrine tumor of the small intestine
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT04735198Prophylactic Cholecystectomy in Midgut NETs Patients Who Require Primary Tumor Surgery.Hospital Universitari de Bellvitge
- ACTIVE NOT RECRUITINGNCT03498040Development and Progression of Carcinoid Heart Disease in a Cohort of Adult Patients With Neuroendocrine TumorsHospices Civils de Lyon
See all trials for Neuroendocrine tumor of the small intestine →